Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $9.25 USD
Change Today +0.1101 / 1.20%
Volume 800.0
As of 11:14 AM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

corium international inc (CORI) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/4/15 - $9.40
52 Week Low
11/17/14 - $4.30
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

corium international inc (CORI) Related Businessweek News

No Related Businessweek News Found

corium international inc (CORI) Details

Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; Crest Whitestrips, which are a series of four products under the Advanced Vivid, Professional Effects, One Hour Express, and Flex-Fit brands for oral care. The company’s products under pipeline comprise AG200-15, a combination hormonal contraceptive patch, which delivers ethinyl estradiol and levonorgestrel hormones has completed a Phase III clinical trial; MicroCor hPTH(1-34), a transdermal system that has completed a Phase I clinical trial for the treatment of severe osteoporosis; and Corplex Tamsulosin that has completed a Phase I clinical trial for the treatment of benign prostatic hyperplasia. In addition, it is developing a generic transdermal product for the prevention of nausea and vomiting associated with motion sickness; a generic transdermal product for the treatment of a urologic condition, as well as Donepezil and Memantine transdermal patches for the treatment of Alzheimer's disease; and Ropinerole and Pramipexole therapies for the treatment of Parkinson's disease. Corium International, Inc. has collaboration agreements with The Procter & Gamble Company; Teva Pharmaceuticals USA, Inc.; Par Pharmaceutical, Inc.; Agile Therapeutics, Inc.; and others. The company was incorporated in 1995 and is headquartered in Menlo Park, California.

244 Employees
Last Reported Date: 12/15/14
Founded in 1995

corium international inc (CORI) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $582.3K
Chief Financial Officer
Total Annual Compensation: $467.3K
Chief Technology Officer and Vice President o...
Total Annual Compensation: $392.2K
Compensation as of Fiscal Year 2014.

corium international inc (CORI) Key Developments

Aequus Pharmaceuticals and Corium Enter into Product Development Collaboration Focused on CNS

Aequus Pharmaceuticals Inc., and Corium International, Inc. announced that they have entered into a collaboration agreement under which the parties may co-fund new transdermal products with an initial focus on neurological disorders. Under the terms of this agreement, for each product selected for development the parties will assign an allocation of responsibilities, costs, rights and product revenues. This collaboration builds upon the progress made under the feasibility and preclinical development agreement entered into in May 2014 focusing on Aequus' lead program, AQS-1301, a transdermal aripiprazole product candidate in development for potential weekly use in the treatment of irritability associated with autistic disorder, bipolar I disorder, schizophrenia and major depressive disorder. The currently available dosage forms of aripiprazole (sold primarily under the trade name Abilify) reached total worldwide sales of over $8 billion in 2014. A once-weekly transdermal patch has the potential to improve medication adherence and reduce the frequency of relapse. Under the earlier agreement, Corium's advanced proprietary transdermal technology was incorporated into Aequus' lead program, AQS-1301, which enhanced the product's intellectual property position, as well as provided Corium with an economic interest in the program and the option to further increase its interest by co-funding clinical development. Aequus has exclusive worldwide rights to AQS-1301 and intends to seek third-party partners to commercialize this program in the U.S., Europe and Asia, while retaining the commercial rights for Canada.

Corium International Appoints Joseph J. Sarret as Chief Business Officer

Corium International, Inc. announced that Joseph J. Sarret, M.D., J.D. has joined the company in the newly created position of Chief Business Officer. Reporting to Corium's President and Chief Executive Officer, Peter D. Staple, Dr. Sarret will serve as a member of the company's executive leadership team with responsibility for developing and implementing Corium's business strategies, building new alliances and expanding existing ones, and pursuing new business initiatives that leverage Corium's advanced transdermal technologies and product candidates. Most recently, Dr. Sarret served as Senior Vice President, Strategic Accounts at Solazyme, Inc., and as Chief Executive Officer and a member of the Board of Directors of Sevident, Inc.

Corium International, Inc. Announces Changes to the Management Team

Corium International, Inc. announced the appointment of Eric H. Bjerkholt to the company's Board of Directors and as Chair of the Board's Audit Committee. Eric Bjerkholt brings a wealth of strategic and management experience in finance, business development, corporate governance and operations in the biopharmaceutical sector. The company look forward to his contributions as a member of its Board as it advance its product programs and continue its rowth as a public company, said Peter Staple, Corium's President and Chief Executive Officer. A senior executive with more than two decades of experience in the healthcare and life science sectors, Mr. Bjerkholt is Executive Vice President, Corporate Development and Finance and Chief Financial Officer of Sunesis Pharmaceuticals, Inc., having joined Sunesis in 2004 as Senior Vice President and Chief Financial Officer. From 2002 to 2004, he was Senior Vice President and Chief Financial Officer at IntraBiotics Pharmaceuticals, Inc. Mr. Bjerkholt was a co-founder of LifeSpring Nutrition, Inc. and from 1999 to 2002 served at various times as its Chief Executive Officer, President, and Chief Financial Officer. He also served as vice president in the healthcare banking group at J.P. Morgan & Co. from 1990 to 1997. Mr. Bjerkholt is a member of the Board of Directors of StemCells, Inc. and Ambrx Inc. The company also announced that John W. Kozarich, Ph.D. will be retiring from the company's Board, and will continue as an advisor to the company. Following Mr. Bjerkholt's appointment as Chair of the Audit Committee on April 1, 2015, David Greenwood stepped down as a member of the Audit Committee and will continue to serve as Chairman of the Board.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CORI:US $9.25 USD +0.1101

CORI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $290.09 USD +0.35
FUJIFILM Holdings Corp ¥4,557 JPY +21.50
Mylan NV $73.41 USD -0.48
Zogenix Inc $1.45 USD +0.015
Zosano Pharma Corp $9.97 USD +0.60
View Industry Companies

Industry Analysis


Industry Average

Valuation CORI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.9x
Price/Book 27.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CORIUM INTERNATIONAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at